Monica A. McArthur, MD, PhD

Texas A&M University (magna cum laude), B.S., Molecular Biology and Microbiology, 1999

The University of Texas Medical Branch, M.D./Ph.D, 2006

Residency, The University of Texas Medical Branch, 2006-2009

Clinical Fellow, University of Maryland School of Medicine, Pediatric Infectious Diseases and Tropical Pediatrics, 2009-2012

Postdoctoral Fellow, University of Maryland School of Medicine Center for Vaccine Development (CVD), Pediatrics, 2012-2013

Dr. McArthur's primary research interests include the interactions between pathogens and the human immune system. She is particularly interested in T cell responses against infectious agents affecting children in the developing world.  Dr. McArthur performs clinical vaccine trials as well as studying translational human immunology.  She serves a PI for the ongoing Novavax Phase 3 COVID-19 vaccine trial (PREVENT-19).  She is also leading a multi-site trial investigating the role of vaccination in reducing asymptomatic or very mildly symptomatic SARS-CoV-2 infection.

https://www.medschool.umaryland.edu/cvd/trials/ 

Pathogens, cellular immunology, T cell response, infectious diseases, vaccine development, vaccine immunology, Zika, flavivirus, SARS-CoV-2, COVID-19.

Dagalakis U, Hammershaimb E, McArthur MA, Macatangay RA.  SARS-CoV-2 infection in pediatric patient with hemoglobin SC disease (Letter to the Editor).  Pediatric Blood and Cancer. 2020 Aug 09

Lin L, Lyke KE, Koren M, Jarman RG, Eckels KH, Lepine E, McArthur MA, Currier JR, Friberg H, Moris P, Keiser PB, De La Barrera R, Vaughn DW, Paris RM, Thomas SJ, Schmidt AC.  Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study. Am J Trop Med Hyg. 2020 Apr 27

McArthur MA, Zhang SL, Li L, Tesh RB, Barrett ADT. Molecular characterization of hamster-adapted yellow fever virus. Vector Borne Zoonotic Dis. 2020 Mar;20(3):222-227

McArthur MA. Zika virus: Recent advances towards the development of vaccines and therapeutics.  Viruses. 2017 Jun 13;9(6):143.

Gaudinski MR, Houser KV, Morabito KM, Hu Z, Yamshchikov G, Rothwell RS, Berkowitz N, Mendoza F, Saunders JG, Novik L, Hendel CS, Holman LA, Gordon IJ, Cox JH, Edupuganti S, McArthur MA, Rouphael NG, Lyke KE,,Cummings GE, Sitar S, Bailer RT, Foreman BM, Burgomaster K, Pelc RS, Gordon DN, DeMaso CR, Dowd KA, Laurencot C, Schwartz RM, Mascola JR,Graham BS, Pierson TC, Ledgerwood JE, Chen GL. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.  The Lancet.  2018. Feb 10;391(10120):552-562

McArthur MA, Fresnay S, Magder LS, Darton TC, Jones C, Waddington CS, Blohmke CJ, Dougan G, Angus B, Levine MM, Pollard AJ, Sztein MB. Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model. PLoS Pathog. 2015 May 22;11(5)e1004914.

McArthur MA, Sztein MB, Edelman RE. Dengue vaccines: recent developments, ongoing challenges, and current candidates. Expert Rev Vaccines. 2013 Aug;12(8):933-53.